focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHutchmed Share News (HCM)

Share Price Information for Hutchmed (HCM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 324.00
Bid: 318.00
Ask: 322.00
Change: 0.00 (0.00%)
Spread: 4.00 (1.258%)
Open: 325.00
High: 325.00
Low: 318.00
Prev. Close: 324.00
HCM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Tekcapital's MicroSalt plans IPO in 2023

Mon, 19th Dec 2022 19:29

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

----------

Tekcapital PLC - London-based intellectual property investor - Announces that its 97%-owned portfolio firm MicroSalt Ltd plans IPO on AIM in 2023. MicroSalt develops and manufactures low-sodium salt. Besides owning about 97% in MicroSalt's portfolio, Tekcapital owns about 73% in MicroSalt's US subsidiary, MicroSalt Inc.

----------

Braemar PLC - London-based shipbroker & advisor in shipping investment - Buys Florida-based Southport Maritime Inc for USD7.3 million. Expects the acquisition to be earnings enhancing in financial year 2024. "Southport is one of the highest volume US-based shipbroking tanker companies. They are recognised as a leader for crude and refined products in the North American export market, as well as in the Latin American and Caribbean markets," Braemar says. Last week Monday, Braemar said it launched a Greek corporate finance desk led by Stefanos Fragos, who used to work for alternative investment platform Yieldstreet Inc, and DVB Bank SE. Braemar last week said it aimed to raise debt and equity to support the Greek shipowners' growth ambitions, explaining that the desk responds to a "clear need" for expert counsel for Greek shipowners.

----------

Gresham Technologies PLC - London-based software and services company - Hails USD1.9 million new customer win with a "tier 1 global asset manager" lasting 3 years. Gresham says: "On 17 December 2022, one of world's largest asset managers signed a contract for Control and Data Services in the cloud to replace a legacy reconciliation product and to streamline its data aggregation processes. The US-based firm, consistently ranked in the top five global asset managers by [assets under management], will partner with Gresham to consolidate all market-facing reconciliations and data controls for their institutional investment management business onto a modern cloud platform."

----------

Hargreave Hale AIM VCT - Blackpool-based venture capital trust - Notes that net asset value per share as at September 30 falls 40% to 60.19 pence from 100.39p a year prior. NAV total return turns to negative 33% from positive 42% a year prior. NAV total return with dividends reinvested is negative 35%, slightly underperforming against its benchmark, the FTSE AIM All-Share Total Return Index, which returns negative 34%. Turns to pretax loss of GBP88.7 million from a profit of GBP67.9 million a year prior. "Russia's invasion of Ukraine, devastating for those directly involved, catalysed an energy shock with profound implications for the economy, households and wider society. Central banks have responded aggressively with immediate consequences for the cost of capital, both to companies and households. The economic outlook, already challenging, got significantly worse," Chair David Brock says. Total financial year 2022 dividend amounts to 6.65p, up 51% from 4.40p a year prior. Looking ahead, the company says: "Recessions spawn innovation and create opportunity. Growth companies will continue to require capital for investment into research, infrastructure, people and working capital. We do not expect the falls endured last year to translate to permanent loss of value. At some point in 2023, we will be able to look forward to better times. As we emerge from recession, fundamentals will improve and markets will recover their poise."

----------

Hutchmed China Ltd - Biopharmaceutical company specialising in discovery and development of cancer and immunological disease treatments - Starts rolling submission of a new drug application of its refractory metastatic colorectal cancer drug candidate fruquintinib to the US Food & Drug Administration. Expects the new drug application to complete in the first half 2023. Notes that its drug reduced death risk by 34% compared to a placebo.

----------

Mirriad Advertising PLC - London-based advertising company, which provides customers with an AI & computer-vision-powered platform that inserts products and signage formats after content is produced - Partners with Scripps Networks to integrate brands across marketplace. Says it will expand Scripps partnership to further brands in Scripps portfolio. Mirriad explains: "Scripps Networks will be able to use Mirriad's platform to integrate brands and products across ION and Bounce, including in new original holiday movies as well as in the blockbuster series, 'Johnson,' and 'Finding Happy' and the newly-announced comedy 'Act Your Age' premiering in the spring of 2023."

----------

Xtract Resources PLC - Australia, Mozambique and Zambia-focused gold producer, exploration and development company - Reports 87 megatonnes at 0.22% grade of copper equivalent at Ascot site as well as 34 megatonnes at 0.3% copper equivalent across Bushranger project in New South Wales, Australia. "The maiden Ascot inferred mineral resource adds a further approximately 190,000 tonnes of copper equivalent metal to the 1.1Mt reported previously at the Bushranger Project," the company says.

----------

By Tom Budszus, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2022 Alliance News Ltd. All Rights Reserved.

More News
7 Feb 2024 09:50

Hutchmed hails fruquintinib trial results for gastric cancer treatment

(Alliance News) - Hutchmed (China) Ltd on Wednesday said phase three data for fruquintinib in combination with paclitaxel showed an improvement in overall survival for patients with gastric or gastroesophageal junction adenocarcinoma.

Read more
2 Feb 2024 09:52

Hutchmed says Inmagene exercises option to licence drug candidates

(Alliance News) - Hutchmed (China) Ltd on Friday said Inmagene Biopharmaceuticals Ltd has exercised options to licence two drug candidates as part of a strategic partnership.

Read more
2 Feb 2024 09:42

Hutchmed partner Inmagene exercises options over two drug candidates

(Sharecast News) - Hutchmed China announced on Friday that Inmagene Biopharmaceuticals has exercised options to licence two drug candidates, IMG-007 and IMG-004, as part of their strategic partnership.

Read more
30 Jan 2024 10:32

Hutchmed's 'Elunate' approved under new Hong Kong rules

(Sharecast News) - Hutchmed China announced the approval of its drug 'Elunate', or fruquintinib, by the Pharmacy and Poisons Board of Hong Kong on Tuesday, for the treatment of adult patients with previously treated metastatic colorectal cancer (CRC).

Read more
30 Jan 2024 09:20

Hutchmed celebrates cancer drug approval in hometown of Hong Kong

(Alliance News) - Hutchmed (China) Ltd on Tuesday touted progress in Hong Kong, after its oral therapy for metastatic colorectal cancer received marketing approval in the city.

Read more
11 Jan 2024 11:11

Hutchmed application for thrombocytopenia treatment accepted in China

(Sharecast News) - Hutchmed China announced on Thursday that the new drug application (NDA) for sovleplenib, an oral inhibitor targeting spleen tyrosine kinase (Syk), had been accepted for review and granted priority review by China's National Medical Products Administration (NMPA).

Read more
11 Jan 2024 10:17

TOP NEWS: Hutchmed Sovleplenib accepted for review by China drug bureau

(Alliance News) - Hutchmed Ltd on Thursday said that its novel treatment for haematological malignancies and immune diseases had been progressed to the next stage of approval by the country's national bureau for drug supervision.

Read more
21 Dec 2023 11:36

IN BRIEF: Hutchmed China renews deals with "substantial" shareholders

Hutchmed (China) Ltd - Hong Kong-based developer of treatments for cancer and immunological diseases - Agrees with "substantial shareholder" Sinopharm Group Co Ltd to renew the Framework Sinopharm Products Supply & Purchase Agreement, effective from January 1, for three years up to and including December 31, 2026. Also agrees with HCMH to renew the HBYS Brand License Royalty agreement, also effective from January 1 and for the same duration. HCMH entered the HBYS deal in June 2021 with HWEL, a subsidiary of major shareholder CK Hutchison Holdings Ltd which holds an approximate 38.18% stake in Hutchmed.

Read more
13 Dec 2023 13:56

Hutchmed completes enrolment for fruquintinib trial

(Alliance News) - Hutchmed (China) Ltd on Wednesday said it has completed enrolment of its phase II/III trial of fruquintinib.

Read more
13 Dec 2023 12:20

Hutchmed completes trial enrolment, keeps drugs on China funding list

(Sharecast News) - Hutchmed China announced a significant milestone in its clinical trials on Wednesday, as well as the inclusion of two of its drugs on the National Reimbursement Drug List (NRDL) in China.

Read more
13 Dec 2023 12:20

Hutchmed completes trial enrolment, keeps drugs on China funding list

(Sharecast News) - Hutchmed China announced a significant milestone in its clinical trials on Wednesday, as well as the inclusion of two of its drugs on the National Reimbursement Drug List (NRDL) in China.

Read more
9 Nov 2023 12:16

Hutchmed hails Takeda's fruquintinib approval from US for cancer form

(Alliance News) - Hutchmed (China) Ltd on Thursday announced that the Tokyo-based drug maker, Takeda Pharmaceutical Co Ltd, has received US approval of fruquintinib for a form of colorectal cancer.

Read more
29 Sep 2023 10:57

Hutchmed confirms new drug application for fruquintinib in Japan

(Sharecast News) - Hutchmed China announced on Friday that its partner Takeda has officially submitted a new drug application (NDA) for fruquintinib to the Ministry of Health, Labour and Welfare (MHLW) in Japan.

Read more
29 Sep 2023 10:12

Hutchmed notes Takeda submits fruquintinib drug application in Japan

(Alliance News) - Hutchmed (China) Ltd on Friday said Takeda Pharmaceutical Co Ltd has submitted a new drug application for cancer treatment fruquintinib to the Ministry of Health, Labour & Welfare in Japan.

Read more
14 Sep 2023 13:09

Director dealings: IPF non-exec picks up shares, Hutchmed China director linked to sale

(Sharecast News) - International Personal Finance was among the companies on the list of director purchases on Thursday after a non-executive director spent more than £18k on shares.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.